Summary

This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

• Semaglutide (Ozempic) is recommended alongside diet and exercise to enhance glycemic control in adults with type 2 diabetes mellitus, and it also lowers the risk of significant adverse cardiovascular events in these patients with established cardiovascular disease.
• The analysis on semaglutide incorporated a total of 18 systematic reviews or meta-analyses.
• Semaglutide has proven highly effective in decreasing HbA1c levels and body weight compared to placebo and several other antidiabetic agents, including DPP-4 inhibitors, SGLT-2 inhibitors, and other GLP-1 receptor agonists, across various patient populations.
• It has shown positive effects in reducing major adverse cardiovascular events (MACE), especially among high-risk patients with type 2 diabetes when compared to placebo. This effect remained consistent across subgroup analyses, highlighting its favorable safety profile in terms of cardiovascular health.
• Emerging studies suggest that GLP-RAs like semaglutide might lessen neurological complications associated with diabetes such as stroke or cognitive impairments, though further investigation is necessary.
• Compared to other GLP-RAs like dulaglutide and liraglutide, particularly at higher doses, indirect treatment comparisons have demonstrated the superior efficacy of semaglutide in both glycemic control and weight reduction.
• Semaglutide's safety profile is consistent with the effects observed within the class of GLP-RAs, showing no significant increase in severe hypoglycemia, pancreatitis, or pancreatic cancer. However, gastrointestinal side effects were reported, which are common within this class of drugs.
• Patients with increased cardiovascular risks have shown consistent benefits while using semaglutide alongside metformin therapy, resulting in decreased all-cause mortality rates and improved cardiovascular outcomes. Additionally, Asians have exhibited pronounced benefits from long-acting GLP-1 RA therapy, including semaglutide, although further research is required in this area.